Solaris Resources Inc. (CVE:SLS – Free Report) – Analysts at National Bank Financial issued their FY2026 earnings per share (EPS) estimates for Solaris Resources in a research report issued on Thursday, May 22nd. National Bank Financial analyst S. Nagle anticipates that the company will post earnings of ($0.08) per share for the year. National Bank Financial also issued estimates for Solaris Resources’ FY2029 earnings at $0.06 EPS.
Separately, Maxim Group downgraded Solaris Resources from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 25th.
Solaris Resources Trading Down 2.7%
SLS stock opened at C$6.15 on Monday. Solaris Resources has a fifty-two week low of C$1.38 and a fifty-two week high of C$7.09. The business’s 50 day moving average price is C$6.15 and its two-hundred day moving average price is C$6.15.
About Solaris Resources
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Further Reading
- Five stocks we like better than Solaris Resources
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- This Market Sell-Off Might Trigger a Value Rotation Into Pepsi
- Investing In Preferred Stock vs. Common Stock
- Alphabet Stock Lags—But Waymo May Be Its Hidden Driver
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Trade Desk Silences Critics; Recovery Looks Poised to Continue
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
